Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.71 |
| ▸ | CA1 | P00915 | 8/20 | 0.71 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA4 | P22748 | 3/20 | 0.61 |
| ▸ | CA6 | P23280 | 3/20 | 0.61 |
| ▸ | CA5A | P35218 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072061 | 0.83 | ALDH1A1 (0.57) | CA2CA1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4964212 | 0.83 | CA2 (1.00) | CA2CA1CA9CA12CA4 | |
| SCHEMBL30849591 | 0.83 | ALDH1A1 (0.57) | CA2CA1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5723996 | 0.83 | CA2 (0.73) | CA2CA1CA9CA12CA4 | |
| SCHEMBL13545180 | 0.82 | CA2 (0.67) | CA2CA1CA9CA12CA4 | |
| SCHEMBL10912165 | 0.82 | ALDH1A1 (0.77) | SMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20738432 | 0.81 | ALDH1A1 (0.77) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2397879 | 0.81 | SMN1; SMN2 (0.65) | CA2CA1CA9CA12CA4 | |
| SCHEMBL2303459 | 0.81 | CA2 (0.65) | CA2CA1CA9CA12CA4 | |
| SCHEMBL13543269 | 0.81 | CA2 (0.65) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-6265581-B1 | REACTING SPECIFIED EPOXIDE AND AMINE, REACTING PRODUCT WITH ACID TO FORM ACID ADDITION SALT | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-4659737-A | Substituted aminomethyl benzopyrans having anti-hypertensive activities | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | disclosed |
| US-4652679-A | Aziridine and phenethanolamine derivatives having antiobesity and anti-hyperglycaemic acitivity | HOFFMANN-LA ROCHE INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4647579-A | Circulation active novel substituted 4-hydroxy-benzopyrans | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | disclosed |
| US-4585796-A | HYPOGLYCEMIC, ANTI-OBESITY | HOFFMANN-LA ROCHE INC. (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | CA2 2584/4885CA1 4866/4885CA9 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.